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Arteriosclerosis, Thrombosis, and Vascular Biology
REVIEWS

Perspectives on Cognitive Phenotypes and
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ABSTRACT: Clinical investigations have established that vascular-associated medical conditions are significant risk factors for various
kinds of dementia. And yet, we are unable to associate certain types of vascular deficiencies with specific cognitive impairments.
The reasons for this are many, not the least of which are that most vascular disorders are multi-factorial and the development of
vascular dementia in humans is often a multi-year or multi-decade progression. To better study vascular disease and its underlying
causes, the National Heart, Lung, and Blood Institute of the National Institutes of Health has invested considerable resources in
the development of animal models that recapitulate various aspects of human vascular disease. Many of these models, mainly
in the mouse, are based on genetic mutations, frequently using single-gene mutations to examine the role of specific proteins
in vascular function. These models could serve as useful tools for understanding the association of specific vascular signaling
pathways with specific neurological and cognitive impairments related to dementia. To advance the state of the vascular dementia
field and improve the information sharing between the vascular biology and neurobehavioral research communities, National Heart,
Lung, and Blood Institute convened a workshop to bring in scientists from these knowledge domains to discuss the potential utility
of establishing a comprehensive phenotypic cognitive assessment of a selected set of existing mouse models, representative
of the spectrum of vascular disorders, with particular attention focused on age, sex, and rigor and reproducibility. The workshop
highlighted the potential of associating well-characterized vascular disease models, with validated cognitive outcomes, that can be
used to link specific vascular signaling pathways with specific cognitive and neurobehavioral deficits.
GRAPHIC ABSTRACT: A graphic abstract is available for this article.
Key Words: atrophy ◼ blood pressure ◼ mutation ◼ risk factors ◼ vascular dementia

VASCULAR DEMENTIA IN HUMANS
Vascular dementia (VaD) in humans is a spectrum of cognitive disorders based on etiology, pathology, and tempo
of cerebrovascular disease.1 Challenges in defining VaD
in human patients include the following: (1) VaD is not a
single condition with a unifying pattern of cognitive deficits, (2) different pathologies (eg, gray matter atrophy,
myelin loss) can manifest as VaD and different vascular and nonvascular etiologies can and often do co-exist,
(3) cognitive deficiency syndromes can be related to a
specific acute event (eg, stroke) or to repeated smaller
insults (eg, small vessel disease), and (4) cognitive

syndrome is, for the most part, a gradually progressive
disorder that primarily affects older individuals with a
spectrum of behavioral, physiological, and neurological
changes that can contribute to cognitive impairment.
To capture the entire spectrum of cognitive disorders
and their heterogeneity, ranging from cognitive impairment to fully developed dementia, a new concept was
proposed in 2011 defined as vascular cognitive impairment (VCI).2,3 A consensus list was developed for neuropsychological evaluations of VCI which includes various
cognitive assessments, imaging, and most recently other
noncognitive assessments (such as alterations in gait)
that have been reported to predict cognitive decline.
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Cognitive Phenotype Assessment of Models of VCID

Nonstandard Abbreviations and Acronyms

Highlights

AD
Alzheimer disease
CADASIL	cerebral autosomal dominant arteriopathy with subcortical infarcts
cSVD
cerebral small vessel disease
NIA
National Institute of Ageing
NINDS	National Institute for Neurological Disorders and Stroke
VaD
vascular dementia
VCI
vascular cognitive impairment
VCID	vascular contributions to cognitive
impairment and dementia

• Vascular cognitive impairment and dementia is a
spectrum of complex set of cognitive and behavioral
disorders. Etiological and pathological heterogeneity
of this syndrome should be taken in consideration in
animal and experimental models.
• Utilization of mice with genetically diverse backgrounds to stimulate human genetic diversity, in
combination with mouse models that best mimic
human disease and consideration of age-appropriate disease manifestations would be of benefit.
• Rigorous phenotypic assessments of a set of existing mouse models of vascular diseases across
behavioral and cognitive assays could provide the
vascular cognitive impairment and dementia field
with a template or standards by which to associate
certain aspects of vascular dysregulation with specific cognitive and behavioral phenotypes in mice.

Downloaded from http://ahajournals.org by on September 19, 2022

In a recent National Heart, Lung, and Blood
Institute-funded clinical study (SPRINT [Systolic Blood
Pressure Intervention Trial])4 that assessed the potential
benefits of reducing blood pressure, authors reported
milder cognitive impairment in the group intensively
treated to achieve a target of <130 mm Hg compared
with those treated to reach <140 mm Hg systolic blood
pressure. Mild cognitive impairment is indisputably a
forerunner for VaD and the National Institute of Neurological Disorders and Stroke (NINDS)-National Institute
of Ageing (NIA)-funded SPRINT MIND 2019 sub-study
of SPRINT5 therefore, raised the possibility that elevated
blood pressure is principally responsible for many more
cases of VaD than previously suspected. The American
Heart Association subsequently revised the threshold for
the diagnosis of hypertension from 140/90 mm Hg to
130/80 mm Hg on the basis that more effective control of blood pressure will have a significant impact in
reducing the incidence of VaD. To date, however, the cellular and molecular mechanisms by which elevated blood
pressure cause VaD remain poorly understood.
Cerebral small vessel diseases (cSVDs) are a major
contributor to VCI and VaD. cSVD an umbrella term
for pathologies that affect the structure or function of
cerebral small vessels, are involved in one-third of ischemic strokes, the vast majority of intracerebral hemorrhages and account for about one-third of all dementia
cases.6–9 A large group of comorbidities, mainly age
and hypertension but also genetic factors, are risk factors for cSVDs.10 Among the important advances in this
research field has been the identification of monogenic
forms of cSVD that share many clinical, neuroimaging
and pathological features with the more common multifactorial cSVDs.11 By far, cerebral autosomal dominant
arteriopathy with subcortical infarcts (CADASIL), caused
by highly stereotyped dominant mutations in NOTCH3
(neurogenic locus notch homolog protein 3), a receptor
predominantly expressed in mural cells of small blood
vessels, is the most common monogenic cSVD and a
paradigm of ischemic cSVD.12,13
832   July 2022

There is currently no treatment available for this devastating disease. With the goal of investigating the CADASIL clinical spectrum, CADASIL-specific mouse models
have been developed using transgene and knock-in technology based on specific individual human CADASIL variants.14 However, most models only recapitulate a portion
of the CADASIL-related pathology, such as altered vascular smooth muscle cell function, while strokes and white
matter changes are not reproduced. There is also a lack of
systematic analyses of neurobehavioral studies in mouse
models to elucidate CADASIL-specific cognitive impairment. It is a major challenge to translate human cognitive impairment into a behavioral readouts that can be
measured and interrogated in mouse studies. Additional
approaches could potentially include more pragmatic utilization of mouse models recapitulating the subcortical
VaD and frontotemporal dementia seen in CADASIL on a
background of CADASIL-specific mouse models.
To best parallel the clinical syndrome of VaD in
humans, animal and experimental models should be cognizant of the etiological and pathological heterogeneity
of this syndrome. These models should include measures of executive function as a salient feature of the
syndrome. Also, while impairments in executive function
and gait anomalies may be early manifestations of VaD,
deficits in attention, memory, and visuospatial domains
are also core features1,15–18 and should be measured in
experimental models.

CURRENT NIA AND NINDS DEMENTIA
RESEARCH STRATEGIES
To overcome historical issues of rigor and reproducibility in disease and behavioral characterization of mouse
models for the study of Alzheimer disease (AD), NIA has
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EXAMPLES OF NATIONAL HEART, LUNG,
AND BLOOD INSTITUTE -FUNDED
VASCULAR DISEASE/DISORDER MOUSE
MODELS
Although some mouse vascular disease models have
been examined for cognitive behaviors, in general, it is
not possible to compare results across models due to
differences in methodology, genetic background, and,
in some cases, poor experimental rigor and reproducibility. Measurement of cognitive phenotypes in animals involves a complex set of processes, variables,
and significant resources and expertise that, while
well characterized and well-understood within the
neuro-cognitive scientific community, are generally
not practiced effectively within the vascular biology
research community.
During the workshop, various mouse models of vascular disease or disorders were presented (Table). The
experimental models discussed included models of

inherited small vessel disease in the brain, atherosclerosis, hypertension, cerebral cavernous malformations,
and intracerebral hemorrhage. Models of inherited blood
disorders, such as sickle cell anemia, and chronic lung
vascular disease, such as chronic obstructive pulmonary
disease were also discussed. Although one of the leading causes of VCI is stroke, discussing experimental
models of hypoperfusion was not in the scope of this
workshop. An increasing number of current research
reports have shown that both sickle cell anemia and
chronic pulmonary disease are associated with cognitive dysfunction. A recent report demonstrated cognitive
deficit in a sickle cell disease mouse model.19 Patients
with chronic pulmonary disease are at higher risk of
developing dementia including patients with chronic
obstructive pulmonary disease.20,21 Additionally, vascular
abnormalities in this group of patients are not limited
to the lung and include multi-system vascular deficiencies in other organs including brain, kidney, and heart
which complicate the course and outcomes of the disease in these patients.22 The various pros and cons with
which these models accurately reflect vascular disease
in humans were also discussed. In general, it was agreed
that none of the models fully reflected the spectrum of
vascular-induced cognitive impairment in humans, but
that each of the models offered specific insights into the
various basic biological processes that likely govern the
development of VCID.
Some of these vascular disease models have been
evaluated for cognitive phenotypes but most have not.
None have been assessed with standard protocols that
enable comparisons with other vascular or AD models.
Furthermore, cross-laboratory reproducibility in the same
mouse models remains a gap. It was suggested that a
rigorous cognitive assessment of a set of existing mouse
models of vascular diseases could provide the VCID field
with a template or standard by which to associate certain
aspects of vascular dysregulation with specific cognitive
and behavioral phenotypes in mice.

MOVING THE FIELD FORWARD
Participants identified the need for multiple animal models to advance the field because VCID is a multi-faceted
disease and more frequently than not, different models
highlight only a few aspects of the human disease. There
was also agreement that some prioritization of models
might be useful, perhaps based on the burden of disease
caused by a given pathology or on other criteria.
Age is a critically important factor in the biology of
VCID and its assessment. The human relevance of specific mouse models can be improved by studying VCID in
aging mice. At the same time, the use of aged animals
greatly increases the cost of experimentation and when
coupled with the need to use both males and females
can create a cost-prohibitive situation for many individual
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been supporting the Model Organism Development and
Evaluation for Late Onset AD initiative, which aims to
create 50 new mouse models focusing on brain pathophysiology, using CRISPR technology. Subsequently, an
in-depth characterization is being conducted by dedicated centers with significant infrastructure and appropriate expertise to align mouse and human phenotypes
with a focus on prioritizing the most translationally relevant phenotypes. Importantly, robust and reliable behavioral outcome measures will be evaluated in tandem with
biomarkers, neuropathology, -omics, and neuroimaging.
The data from Model Organism Development and
Evaluation for Late Onset AD, including mouse strains,
data types, studies, and assays are available to the scientific community on the AD Knowledge Portal (https://
adknowledgeportal.org).
The NINDS strategic approach is closely aligned
with NIA vision and objectives. Understanding vascular contributions to cognitive impairment and dementia (VCID) is a priority identified in the National Plan
to Address AD. NINDS supports mechanism-oriented
VCID research such as better understanding of the
neurovascular unit, the impact of cerebrovascular and
cardiovascular disease insults, and the various effects
of proteinopathies, metabolic disease, and immune
response on cognitive function.
Together, NIA and NINDS have recognized the need
for supporting multi-institutional, multidisciplinary centerbased initiatives that emphasize best practices in animal
model development and characterization, with milestonedriven objectives as resources for the greater research
community with a focus on improving preclinical to clinical translation that emphasizes rigor, reproducibility, and
Open Science principles.

Cognitive Phenotype Assessment of Models of VCID
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Table. Representative Mouse Models of Vascular Disease-Related Cognitive Impairment
Disease/presenter

Disease characteristics

Model(s)

Challenges and limitations

CADASIL
Manfred Boehm, MD

Rare, inherited small vessel SVD, caused by
mutation in the Notch3 gene and characterized by white matter lesions, that leads to
vascular dementia. Studies of human subjects identified impaired memory, decreased
psychomotor skills, and loss of executive
function as symptoms, suggesting it may be
a front subcortical-type syndrome.

Several CADASIL/Notch3
models exist; most are
transgenic

A potential approach to study subcortical vascular
dementia would be to use ApoE-deficient mice subjected to bilateral cortical artery stenosis and placed on
a high-fat diet, to induce hyperlipidemia.

CADASIL
Anne Joutel, MD, PhD

Monogenic SVD diseases

TgNotch3R169C on a
C57BL/6 background

A translationally relevant model of the most common
genetic form of ischemic SVD that recapitulates the
early stage of the disease and has few limitations.

CADASIL

Downloaded from http://ahajournals.org by on September 19, 2022

ICH
Anne Joutel, MD, PhD

ICH

Col4a1 mutant
mice (Col4a1∆ex41/+,
Col4a1G498V/+,
Col4a1G1064D/+)

Translationally relevant models of the most common
genetic form of hemorrhagic SVD that faithfully recapitulate the full spectrum of the human disease; however,
these models have major limitations.

CCMs
Mark Kahn, MD

CCMs are thin-walled, dilated vascular malformations, caused by loss-of-function mutations in CCM genes: CM1 (KRIT1), CCM2,
or CCM3 (PDCD10). CCMs can lead to
neurological deficits, seizures, and hemorrhagic stroke.

Kritfl/fl, R26-LSL,
Pik3caH1047R + AAV-Cre

The first neonatal model developed was thought to
be a true animal model for CCM but did not confer
disease in adult animals like in humans. Addressing the
deficiency of the model revealed a mechanism underlying the human disease. A new adult mouse model was
developed that is now being used for preclinical testing
of drugs vs CCM disease.

SCD
Hyacinth Hyacinth, MD,
PhD

Poor neurocognitive performance such as
loss of full-scale IQ is a significant complication of SCD. Neurostructural changes, in
addition to cerebral vasculopathy, are potential mechanism of cognitive and behavioral
complications of SCD.

Townes sickle cell with
humanized control mice

Model has been in use for over 2 decades and is
well-characterized; it has documented cerebral microvascular, neuronal, and cognitive changes; the model
phenotype is similar to that observed in humans and is
thus highly translational; behavioral characterization has
included novel object recognition and fear conditioning.
However, the mice have significant motor impairments
which may confound the ability to perform these tests.

Chronic lung vascular
disease
Kurt Stenmark, MD

COPD affects >200 million people, with
cognitive impairment in up to 60 percent of
certain populations. Systemic vascular inflammation is seen in the vascular COPD phenotype with a high level of XOR expression in
inflammatory macrophages in the adventitial/
perivascular region of the hypertensive pulmonary artery; COPD patients with pulmonary hypertension have higher levels of serum
uric acid, which is associated with dementia.

Transgenic uricase KO
mice

The complex metabolic environment of the human body
is often not recapitulated in rodent models due to presence of an active uricase gene. Backcrossing uricase
KO mice in the Denver altitude with serial tapering of
an XOR inhibitor, allopurinol, led to a KO phenotype
that can stay alive and breed without the necessity of
allopurinol. This provided a very useful model that can
mimic the deleterious effects of chronic hyperuricemia
on systemic vasculature similar to humans.

Hypertension
Alan Daugherty, PhD,
DSc

Hypertension is the most common chronic
disease in the world. The precise cause of
elevated blood pressure cannot be determined in most people.

Infusion of angiotensin II
in C57BL/6J, ApoE −/−,
and smooth muscle cellspecific LRP1 deletion

Role of hypertension in mouse models of cognitive
disorders needs awareness of the following: Distinction
of pressure per se vs multiple stimuli that can promote
hypertension; regional specific effects on different
vascular beds; vascular phenotypes display sex-specific
effects; and background strain differences. Accurate
sequential blood pressure measurements without affecting physiological condition are challenging.

Atherosclerosis
Alan Daugherty, PhD,
DSc

Atherosclerosis is a progressive disease with
evolving pathology. Lesion formation has
regional specificity; lesion composition may
have regional specificity. The effects of atherosclerosis per se on cognitive impairment
need to be defined.

ApoE−/−, human apoB
transgenic, and low-density lipoprotein receptor
(LDLR−/−)

ApoE−/− mice have cognitive impairment,23–25 but ApoE
has many effects, so the link to atherosclerosis has not
been established. LDLR−/− mice have cognitive impairment, but the effects of hypercholesterolemia vs atherosclerosis need to be defined.

CADASIL indicates cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy; CCM, cerebral cavernous malformations; COPD,
chronic obstructive pulmonary disease; ICH, intracerebral hemorrhage; KO, knockout; LRP1, LDL receptor related protein 1; NOTCH3, neurogenic locus notch homolog
protein 3; SCD, sickle cell disease; SVD, small vessel disease; and XOR, xanthine oxidoreductase.

laboratories. Thus, center-based funded initiatives such
as those being conducted by Model Organism Development and Evaluation for Late Onset AD as described
above, may provide an opportunity to address these
issues. Additionally, it was recognized that utilization
of mice with genetically diverse backgrounds to mimic
834   July 2022

human genetic diversity will be of importance. Furthermore, genetic diversity in combination with mouse models that best mimic human disease at the genetic level
(point mutations, rather than transgenics for example)
taking into consideration age-appropriate disease manifestations would be of benefit.
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There are many challenges, limitations, and confounding
factors when attempting to measure cognitive function
and behavioral phenotypes in mouse models. Multiple variables can affect intra- and inter-lab reproducibility, including task type, task duration, environmental conditions, time
of day, and pretest and posttest subject treatment. These
many considerations need to be reported to ensure reproducibility. In addition, multiple factors can act as confounders in behavioral assays and result in misinterpretation of
data, for example, aging-dependent visual impairments
and hyperactivity. To ensure rigor and reproducibility, scientists should follow the Animals Research: Reporting of In
Vivo Experiments guidelines26 for experimental research,
use appropriate control animals, establish a priori inclusion and exclusion criteria, predetermine sample sizes
based on power analyses, randomize and counter-balance
experimental conditions, and maintain data blinding until
the completion of the analysis, and ensure that the personnel conducting these tests are properly trained.
Standardization with well-delineated standard operating procedures is critical for high-throughput cognitive
assessments and comparison across multiple models.
Validated training of experimental personnel is essential
as is consultation with experts in the field to ensure the
most appropriate experimental design and testing battery.
Commonly used traditional methods to assess cognition in
mice and rats can have serious shortcomings since these
approaches do not represent cognition tests in human
participants. Future innovations include more video/image
data, the use of artificial intelligence and neural networks for analysis, longitudinal phenotyping, and deeper,

richer, more translatable data sets. Newer methodologies,
including virtual technology- and machine-learning based
behavioral assessments may also provide more effective
alternative to traditional behavior tests.27 One such new
methodology, touchscreen cognitive testing (Figure [A]),
may provide improved translation over traditional behavioral assays that can capture a spectrum of phenotypes
in a standardized testing battery. Touchscreen cognitive
testing is an automated, high-throughput method that
enables tests of disease-relevant, high-level cognition
that are identical in all important respects to those used
to assess humans, such as the Cambridge Brain Sciences
(cambridgebrainsciences.com) and CANTAB (https://
www.cambridgecognition.com/cantab/) batteries. This
method allows for flexible presentation of comprehensive
tests involving visual stimuli presented at any location on
a computer screen. Over 30 validated touchscreen tests
(Figure [B]) are available for mice and rats to tap into
disease-relevant aspects of high-level cognition including attention, memory, executive function, and motivation.
These protocols are analogous to the touchscreen based
CANTAB assessments presented in the clinic including
delayed match and delayed nonmatch to sample, paired
associates learning, pairwise discrimination and reversal learning, and 5-choice continuous performance task,
among others. Protocols for an extensive battery of touchscreen tests were published in 3 invited, back-to-back
papers in Nature Protocols.28–30 Touchscreen cognitive
testing enables high-throughput testing with standardization and reproducibility through computer automation,
reduced human error, reduced stress on animals, and tests
similar to those used with humans to increase translatability. It is also amenable to open science and data sharing.
Given that no single animal model can recreate all human
VCID pathologies, it is increasingly important to evaluate
multiple vascular disease mouse models using a common
experimental framework and to facilitate comparison of
results across distinct models.

OTHER FACTORS/MEASUREMENTS THAT
SHOULD BE INCLUDED
Other possible factors to consider include genetics
(background, strain, and substrain,31 rare versus common
disease, transgenic versus knock-out, etc), aging, sex as
a biological variable, environmental factors (feed, microbiome, lighting, background noise, time of day, handling,
etc), appropriate controls (wild-type littermates), and
cohorting (batching).32 Discussants indicated all these
are important factors that need to be fully reported.
The workshop participants agreed that some type of
brain imaging modality should also be incorporated into
any set of measurements that seeks to have a comprehensive assessment of cognition or cognitive-like phenotypes
associated with vascular disease mouse models. In vivo
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• More emphasis on histological assessments and
increased use of advanced functional imaging technologies, such as magnetic resonance imaging.
• Enhanced characterization of human brain vasculature from patients to better characterize pathophysiological mechanisms of disease.
• The measurement of phenotypes with no known
brain pathology, such as hyperactivity and gait to
set the standard for healthy to be compared with
the VCID pathology.
• Increased attention to environment and animal husbandry issues as they relate to animal behavior.
• Careful analysis of confounding behaviors in mice
to avoid mis-interpretation of cognitive outcomes
that may be a result of other physical impairments
(eg, motor function, vision).
• Focus on mouse genetic models, but with awareness that point mutations would have more distinct
effects than knockout models or transgenics.

Cognitive Phenotype Assessment of Models of VCID
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Figure. Touchscreen cognitive testing.
A, The rodent touchscreen operant chamber in use. Experimental mice respond directly to the stimuli. B, Rodent touch screen tests.
Downloaded from http://ahajournals.org by on September 19, 2022

imaging provides significant opportunities to measure cerebrovascular functioning that can be accomplished uniquely
in the mouse. Magnetic resonance imaging was the most
commonly mentioned and preferred imaging modality, but
again, affordable access to all laboratories can be problematic. Importantly, correlating behavioral outcomes in rodents
with pathological and biochemical changes will be key for
translation. It is also worth noting that not all behavioral
endophenotypes in human patients have an analogous
mouse behavior or reciprocally, that some mouse behaviors
are not analogous to humans, for example, human bipedal
gait versus mouse quadrupedal gait.33

HOW TO ENSURE RIGOR AND
REPRODUCIBILITY IN THE OUTCOMES
Rigor and reproducibility in biomedical research are
essential for discoveries to be translated into improved
human health. Several recent reports, including the
National Institutes of Health Advisory Committee to the
Director Report on Enhancing Rigor, Transparency, and
Translatability in Animal Research,34 as well as the findings in a Nature35 report, list factors that can improve or
reduce reproducibility.
Biased reporting and time pressure to publish have
been cited as 2 significant causes of irreproducibility. Other factors include failure to conduct adequate
836   July 2022

statistical sample size calculations and subsequent statistical analysis, and accounting for experimental animals
of both sexes. Increasingly, for experiments that seek to
measure complex phenotypes and behaviors, such as
cognition, it is essential to have a robust statistically justified sample size, well-defined experimental end points,
appropriately chosen experimental controls instead of
historical data, methods for randomization and counterbalancing, and blinded assessments.
Assay proficiency metrics and cross-lab training are
important elements of rigor. There is also a need to
establish reproducibly measured positive controls under
the experimental conditions being used and appropriate
assays for what is being measured. The use of dedicated
centers to ensure standardized evaluations of complex
phenotypes by fully trained personnel with well-calibrated equipment should also be considered.

FINAL THOUGHTS ON THE
COMPREHENSIVE ASSESSMENT
RECOMMENDATIONS
National Heart, Lung, and Blood Institute has been actively
participating in and convening workshops to determine
the state of science in VCID to facilitate research on key
gaps and the need for new model systems to truly represent the human disease.36,37 This workshop identified
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